Journals / The Anatolian Journal of Cardiology / 2016 / Cilt: 16 - Sayı: 4

Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats

Pages
234–241
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A p<0.05 value was accepted as statistically significant.Results: Our results showed that doxorubicin treatment caused significant deterioration in left ventricular functions by echocardiography, histological heart tissue damage, and increase in cardiomyocyte apoptosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The clinical use of doxorubicin, which is a strong antineoplastic agent, is limited due to its cardiotoxic side effects.
📊
Key Findings & Data:Forty male, 10-week-old Wistar albino rats were randomly divided four groups.
💡
Conclusion & Impact:A p<0.05 value was accepted as statistically significant.Results: Our results showed that doxorubicin treatment caused significant deterioration in left ventricular functions by echocardiography, histological heart tissue damage, and increase in cardiomyocyte apoptosis.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The clinical use of doxorubicin, which is a strong antineoplastic agent, is limited due to its cardiotoxic side effects. Metformin is a drug with antihyperglycemic effects, and it has been shown to have a cardioprotective effect on left ventricular function in experimental animal models of myocardial ischemia. The present study investigated the cardioprotective effect of metformin in rats with doxorubicin cardiotoxicity.Methods: Wistar albino rats were used in the study. Forty male, 10-week-old Wistar albino rats were randomly divided four groups. The control group rats were intraperitoneally administered saline solution twice a week, four doses in total. The doxorubicin group rats received doxorubicin (4 mg/kg, twice a week, cumulative dose: 16 mg/kg) intraperitoneally. The metformin group rats received metformin (250 mg/kg/day, every day for 14 days) via gavage. The doxorubicin + metformin group rats received doxorubicin and metformin at the same dose. Left ventricular functions were evaluated by using M-mode echocardiography one day after the last dose of doxorubicin. Heart tissue samples were histopathologically examined. Cardiomyocyte apoptosis was detected using in situ terminal deoxynucleotide transferase assay (TUNEL). Serum brain natriuretic peptide and C-type natriuretic peptide levels were measured. Catalase, superoxide dismutase, glutathione peroxidase, and tumor necrosis factor alpha levels were analyzed in the heart tissue. The assumptions of equality of variances and normal distribution were checked for all variables (Shapiro-Wilk test and Q-Q graphics).To identify intergroup differences, one-way variant analysis or the Kruskal-Wallis test was used. A p<0.05 value was accepted as statistically significant.Results: Our results showed that doxorubicin treatment caused significant deterioration in left ventricular functions by echocardiography, histological heart tissue damage, and increase in cardiomyocyte apoptosis. Doxorubicin + metformin group showed protection in left ventricular function, elimination of histopathologic change, and reduced of cardiomyocyte apoptosis.Conclusion: The present study provided evidence that metformin has cardioprotective effects against doxorubicin cardiotoxicity

🔖

Cite This Article

ARGUN, M., ÜZÜM, K., SÖNMEZ, M. F., ÖZYURT, A., KARABULUT, D., SOYERSARICA, Z., ÇİLENK, K. T., UNALMIŞ, S., PAMUKÇU, Ö., BAYKAN, A., NARİN, F., ELMALI, F., NARİN, N. (2016). Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 4, 234–241. https://ajindex.com/articles/365417

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Hareke D, Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiotoxicity in childhood cancer survivors: strategies for preven- tion and management. Future Cardiol 2012; 8: 647-70. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006; 57: 485-98.
  2. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, et al. Late mortality experience in five-year survivors of child- hood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19: 3163-72.
  3. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339: b4606. Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 2004; 22: 769-73.
  4. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmocokinetics and pharmacodynamics. Pharmacogenet Genomics 2012; 22: 820-7.
  5. El Messaoudi S, Rongen GA, de Boer RA, Riksen NP. The cardio- protective effects of metformin. Curr Opin Lipidol 2011; 22: 445-53.
  6. Ashour AE, Sayed-Ahmed MM, Abd-Allah AR, Korashy HM, Maayah ZH, Alkhalidi H, et al. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats. Oxid Med Cell Longev 2012; 2012: 434195. Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail 2014; 16: 358-66.
  7. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561-78.
  8. Asensio-Lopez MC, Sanchez-Mas J, Pascual-Figal DA, Abenza S, Perez-Martinez MT, Valdes M, et al. Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin- induced cardiotoxicity. Free Radic Biol Med 2013; 157: 188-200. van Staa TP, Patel D, Gallagher AM, de Brui ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012; 55: 654-65.
  9. Charlon V, Boucher F, Mouhieddine S, de Leiris J. Reduction of myocardial infarct size by metformin in rats submitted to perma- nent left coronary artery ligation. Diabetes Metab 1988; 14: 591-5.
  10. Paiva M, Riksen NP, Davidson SM, Ha